Version 1
: Received: 21 October 2024 / Approved: 21 October 2024 / Online: 21 October 2024 (12:37:38 CEST)
Version 2
: Received: 29 October 2024 / Approved: 29 October 2024 / Online: 30 October 2024 (05:04:22 CET)
How to cite:
Min, C.; Zhong, X.; Cui, Y.; Zhang, H.; Wang, Q. Strategies for Salvage Therapy Post CAR-T Therapy Failure in Refractory/Relapsed Multiple Myeloma Patients. Preprints2024, 2024101578. https://doi.org/10.20944/preprints202410.1578.v2
Min, C.; Zhong, X.; Cui, Y.; Zhang, H.; Wang, Q. Strategies for Salvage Therapy Post CAR-T Therapy Failure in Refractory/Relapsed Multiple Myeloma Patients. Preprints 2024, 2024101578. https://doi.org/10.20944/preprints202410.1578.v2
Min, C.; Zhong, X.; Cui, Y.; Zhang, H.; Wang, Q. Strategies for Salvage Therapy Post CAR-T Therapy Failure in Refractory/Relapsed Multiple Myeloma Patients. Preprints2024, 2024101578. https://doi.org/10.20944/preprints202410.1578.v2
APA Style
Min, C., Zhong, X., Cui, Y., Zhang, H., & Wang, Q. (2024). Strategies for Salvage Therapy Post CAR-T Therapy Failure in Refractory/Relapsed Multiple Myeloma Patients. Preprints. https://doi.org/10.20944/preprints202410.1578.v2
Chicago/Turabian Style
Min, C., Hanfu Zhang and Qingming Wang. 2024 "Strategies for Salvage Therapy Post CAR-T Therapy Failure in Refractory/Relapsed Multiple Myeloma Patients" Preprints. https://doi.org/10.20944/preprints202410.1578.v2
Abstract
Over the past few decades, the landscape for multiple myeloma (MM) therapy has significantly advanced, largely due to the approval and introduction of new-generation proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs). Despite these advancements, MM remains incurable. In March 2021, the U.S. FDA approved the chimeric antigen receptor T-cell (CAR-T) therapy idecabtagene vicleucel (ide-cel) for relapsed/refractory multiple myeloma (R/R MM), heralding the advent of cellular therapies for R/R MM. However, due to factors such as the downregulation or loss of tumor antigen expression, T-cell exhaustion, and the influence of the tumor immune microenvironment, most R/R MM patients inevitably experience relapse following CAR-T cell therapy. Consequently, salvage therapy in the post-CAR-T setting has emerged as a critical area of research. This review discusses the potential factors leading to CAR-T therapy failure in R/R MM patients and discusses subsequent salvage therapeutic strategies, offering recommendations for addressing treatment failure in this context.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
